CenterBook Partners LP Has $3.58 Million Stock Position in Mirum Pharmaceuticals, Inc. $MIRM

CenterBook Partners LP increased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 442.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 45,367 shares of the company’s stock after buying an additional 37,010 shares during the quarter. CenterBook Partners LP’s holdings in Mirum Pharmaceuticals were worth $3,584,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Mirum Pharmaceuticals by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock worth $205,065,000 after buying an additional 50,720 shares during the period. Geode Capital Management LLC raised its stake in Mirum Pharmaceuticals by 5.2% during the 4th quarter. Geode Capital Management LLC now owns 1,062,926 shares of the company’s stock worth $83,975,000 after buying an additional 52,904 shares during the period. Wellington Management Group LLP raised its stake in Mirum Pharmaceuticals by 566.8% during the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after buying an additional 672,118 shares during the period. Goldman Sachs Group Inc. raised its stake in Mirum Pharmaceuticals by 60.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 724,317 shares of the company’s stock worth $57,214,000 after buying an additional 273,479 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its stake in Mirum Pharmaceuticals by 709.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock worth $44,889,000 after buying an additional 536,674 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MIRM. Citizens Jmp reaffirmed a “market outperform” rating and set a $132.00 price target on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 21st. Leerink Partners dropped their price target on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. TD Cowen upped their price target on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Citigroup began coverage on Mirum Pharmaceuticals in a research note on Tuesday, June 2nd. They set a “buy” rating and a $145.00 price target on the stock. Finally, Wall Street Zen downgraded Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $137.64.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $93.58 on Tuesday. The company has a market cap of $5.71 billion, a PE ratio of -6.88 and a beta of 0.50. Mirum Pharmaceuticals, Inc. has a 52 week low of $45.37 and a 52 week high of $114.99. The business has a 50 day moving average price of $97.38 and a 200-day moving average price of $90.52. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing the consensus estimate of ($0.75) by ($12.68). The company had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The business’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same period last year, the company earned ($0.30) earnings per share. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Peter Radovich sold 16,515 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $1,519,049.70. Following the completion of the transaction, the chief operating officer directly owned 40,272 shares of the company’s stock, valued at $3,704,218.56. This represents a 29.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Joanne Quan sold 7,287 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $670,258.26. Following the completion of the transaction, the insider directly owned 18,864 shares of the company’s stock, valued at approximately $1,735,110.72. This represents a 27.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 106,806 shares of company stock valued at $9,939,816 over the last quarter. Corporate insiders own 8.32% of the company’s stock.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.